ASP Isotopes Q3 10-Q Report
11/20/25
ASP Isotopes Inc. (ASPI) – Q3 2025 Tear Sheet
Snapshot & Investment Thesis
Ticker: ASPI
Share Price (11/20/2025): $6.71
Shares Outstanding: 93.4M
Market Cap: $626.6M
Pro Forma Cash: $313.6M ($3.36/share)
Current Position: STRONG BUY
2026/27 Price Targets:
Bear Case: $10–18 (+49% to +168%)
Base Case: $25–30 (+273% to +347%)
Bull Case: $45–60 (+571% to +794%)
Quarter Summary – Q3 2025 (Sep 30)
Major Performance Metrics
Total Revenue: $4.89M (+349% YoY, +308% QoQ)
Specialist Isotopes Revenue: $1.27M (PET Labs: radiopharma doses)
Construction Services (Skyline): $3.62M (acquired segment, one month contribution)
Gross Profit: $423K (margin: 8.7%, down from 47.7% QoQ, mainly due to Skyline mix)
Operating Expenses: $15.4M (R&D: $3.1M, SG&A: $12.3M)
Net Loss: $(12.9)M (wider YoY and QoQ; includes non-cash accounting)
Current Assets: $174M | Current Liabilities: $28.3M | Current Ratio: 6.1x
Working Capital: $145.7M | Book Value/Share: $1.03 (+203% QoQ)
Burn Rate: ~$5–6M/quarter net, >14 years runway at present liquidity
No dilution risk; recent financings at premiums to book
Recent Major Updates & Acquisitions
Skyline Builders Acquisition:
QLE acquired 79% of Hong Kong-based Skyline for US$2.5M, bringing $3.62M revenue and $9.1M in cash in Q3 alone.
Provides civil/utility infrastructure expertise and $40–50M/yr stable revenue. Strategic ballast & supply chain leverage.
Capital Raises:
June, July, Oct 2025: Raised >$300M total; key raise at $12.25/share post-Q3, boosting pro forma cash to $313.6M (50% of share price now backed by cash).
No further raises expected thru 2027.
QLE Nuclear Fuels IPO:
QLE submitted confidential S-1 for spin IPO (expected Q4 2025/Q1 2026); separates nuclear fuel unit, unlocks $1.1–2.6B value for ASPI shareholders.
TerraPower Partnership:
QLE secured $22M loan and supply agreements for HALEU; 10-year, 150 MT contract (potential $500M+ revenue).
Strategic Investments:
$30M secured bridge loan to Renergen for SA nuclear site adjacency; vertical investment in IsoBio (precision radioisotopes), plus nuclear waste (One 30 Seven, $17M+ milestones/royalties optionality).
Key Quarterly Developments
Three Enrichment Plants Online:
All facilities in Pretoria fully commissioned and producing samples (C-12, Si-28, Yb-176).
First C-12 shipment expected Q4 2025, Si-28 in Q1 2026; Yb-176 (radiotherapeutics) and C-14 ramping H1 2026.
Revenue Inflection Point Arrived:
Multi-segment revenue began Q3 as Skyline acquired and PET Labs scaled.
Revenue mix moving toward >70% specialist isotopes in FY 2026 as commercial shipments start.
Balance Sheet Strengthened:
Book value/share up 203% QoQ; $112M in new cash QoQ (+68%), $51M working capital increase from prior quarter.
Accounts receivable exploded due to new construction segment ($17.4M), signal for future recognized revenue.
Operating Leverage Emerging:
SG&A up only 5% QoQ despite 241% equity increase; R&D rising, but as a percent of equity, beginning to fall as ramp approaches.
KPI/Value Add Stats
Quarterly Revenue Growth: +308% QoQ, +349.5% YoY.
Pro Forma Cash Per Share: $3.36 (post-Oct 2025), >50% of stock price
Runway: >14 years at net burn, no equity raise risk
Gross Margin: 8.7% Q3 (Skyline mix drag), expects 40–70% as isotopes become dominant revenue line
Revenue Blend: Sep 2025: 74% construction, 26% isotopes; targeted 70%+ isotopes in FY 2026
Market Cap to Book Value: 6.5x
2027E Revenue: $75–250M across scenarios
Major Contract: TerraPower 10-yr/$500M+ supply deal (HALEU)
IPO Catalyst: QLE IPO expected to unlock $1.1–2.6B value (ASPI retains 75–80%)
Accounts Receivable Jump: +2,583% QoQ, leading indicator for recognized revenues
Things to Watch / Forward Catalysts
Q4 2025: First C-12 commercial shipment (validates ASP tech, drives inflection)
Q1 2026: QLE IPO; Si-28 quantum computing shipment
FY 2026: Revenue ramp, gross margin mix shift to isotopes
TerraPower contract execution: Facility construction milestones, supply launches
Isotope customer acceptance: Key for Si-28 and Yb-176 pricing power
Regulatory Approvals: HALEU plant licensing for QLE in South Africa, timeline monitor
Renergen/One 30 Seven outcomes: Asset acquisition or loan repayment, nuclear waste royalty scaling
Risks
Execution (Commercial, Regulatory): HALEU regulatory delays, customer acceptances
Isotope Pricing/Competition: Niche pricing risk, offset by supply scarcity
Balance Sheet Mitigation: $313.6M cash reserves, Skyline cashflow
Strategic Outlook – 2026/2027
Revenue scaled by multiyear isotope shipments, Skyline cash engine, and QLE nuclear fuel option.
QLE IPO and TerraPower deal to reposition ASPI as specialty isotope + nuclear fuel “pure-play.”
Expect 2–4x valuation expansion as revenue and earnings ramp catalyze growth narrative.
Management executing on every milestone with capital discipline and accretive dealmaking.
FULL 16-PAGE REPORT AND OUTLOOK ATTACHED BELOW
The full report delivers an original scenario framework that quantifies how revenue ramp, facility milestones, and sum-of-the-parts valuation drive a highly differentiated 273–794% upside range.
It provides an institutional breakdown of all operational inflection drivers, with granular 2027 segment targets and market data for quantum computing, nuclear fuel, and isotope markets, pairing this with capital allocation analysis that ties every major contract, deal, and investment to equity value creation.
You will find rigorous, buy-side-quality risk and catalyst modeling, with scenario sensitivities and mitigation plans spelled out for every key risk, from technical yields to regulatory timelines and pricing power.
Clear articulation of why this is the final pre-commercial quarter to own ASPI, as a cluster of near-term milestones (QLE IPO, first shipments, rev mix shift) are set to force a major re-rating.
All valuation work is supported by proprietary detailed financials, showing explicitly how management execution, layered capital structure, and strategic partnerships set up a rare multi-bagger opportunity.
FULL REPORT HERE:
